Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients

Phase 1CompletedNCT05195918

Hal Chapman50 enrolled

Overview

The primary purpose of this multi-center, double-blind, placebo-controlled, dose-ranging Phase I study is to assess the safety of a purified from green tea, EGCG, in patients with idiopathic pulmonary fibrosis (IPF) as a potential novel treatment for pulmonary fibrosis.

This is a multi-center, double-blind, placebo-controlled, dose-ranging Phase I study of once daily EGCG administered for 12 weeks. The study will assess safety, pharmacokinetics, and biomarker measurements of drug effect in IPF patients already receiving background therapy for IPF with either nintedanib or pirfenidone. Two different doses of EGCG will be studied. The rationale for this study is 1) extensive pre-clinical data in mice that EGCG is efficacious in attenuating pulmonary fibrosis by blocking collagen cross-linking and the pro-fibrotic pathway mediated by TGFβ1 signaling and 2) recently published data demonstrating that in humans EGCG is safe and capable of blocking lung tissue pro-fibrotic signaling when given two weeks prior to diagnostic surgical biopsy of pulmonary fibrosis patients, many of whom were subsequently diagnosed with IPF.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

EGCG 300 mg + NintedanibCOMBINATION_PRODUCT

Dietary Supplement: EGCG Capsules with Teavigo EGCG (at least 94% purity). 300 mg EGCG (2 capsules) taken orally daily for 12 weeks. Drug: Nintedanib

EGCG 300 mg + PirfenidoneCOMBINATION_PRODUCT

Dietary Supplement: EGCG Capsules with Teavigo EGCG (at least 94% purity). 300 mg EGCG (2 capsules) taken orally daily for 12 weeks. Drug: Pirfenidone

Placebo 2 capsules + Nintedanib or PirfenidoneCOMBINATION_PRODUCT

Dietary Supplement: Placebo Placebo (2 capsules) taken orally daily for 12 weeks. Drug: Nintedanib Drug: Pirfenidone

Eligibility

Sex: ALLMin age: 40 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Provision of signed and dated informed consent form. 2. Stated willingness to comply with all study procedures and availability for the duration of the study. 3. Male or female, aged 40-85 years old. 4. Participant has IPF satisfying the 2022 ATS diagnostic criteria, confirmed by enrolling investigator at Visit 1. 5. Participant must have been on a stable dose of nintedanib twice daily or pirfenidone three times daily dose for at least 12 weeks prior to baseline (Visit 2). 6. Participant has a FVC ≥ 50% predicted using the global lung function initiative (GLI). 7. Participant has a DLCO corrected for hemoglobin ≥ 35% predicted using the GLI. 8. Women of child bearing potential (WCBP), defined as a sexually mature woman not surgically sterilized or not post-menopausal for at least 24 consecutive months if \< 55 years or 12 months if \> 55 years, must have a negative serum pregnancy test within 1 week prior to the first dose of study drug and must agree to use adequate methods of birth control throughout the study. Adequate methods of contraception include use of oral contraceptives or Depo-Provera, with an additional barrier method (diaphragm with spermicidal gel or condoms with spermicide), double-barrier methods (diaphragm with spermicidal gel and condoms with spermicide), partner vasectomy, and total abstinence. 9. Participant has a life expectancy of at least 9 months at Visit 1. 10. Ability to take oral medication and be willing to adhere to EGCG regimen. 11. Agreement to refrain from drinking green tea in excess of a cup a day or eating green tea extract for 4 weeks before baseline and during the trial. Exclusion Criteria: 1. AST, ALT, or direct bilirubin above upper limit normal from any cause at the Screening Visit. 2. Any history of HCV or HBV infection, NASH/NAFLD, or cirrhosis. 3. Alcohol consumption greater than 7 drinks per week. 4. Participant has emphysema ≥ 50% or the extent of emphysema is greater than the extent of fibrosis as per interpretation of Site Investigator or radiologist. 5. Participant has received investigational therapy for IPF within 4 weeks before baseline (Visit 2). 6. Participant is receiving systemic corticosteroids equivalent to prednisone \> 10 mg/day or equivalent within 2 weeks of baseline visit (Visit 2). 7. Participant has any concurrent condition other than IPF that, in the Investigator's opinion, is unstable and/or would impact the likelihood of survival for the study duration or the participant's ability to complete the study as designed, or may influence any of the safety or efficacy assessments included in the study. 8. Participant has baseline resting oxygen saturation of \< 89% on room air or need for continuous oxygen use at baseline visit (Visit 2). 9. Consumption of GTE products in excess of a cup of green tea a day within one month of the baseline visit (Visit 2). 10. Participant is receiving digoxin at the time of screening (Visit 1) and for the duration of the study. 11. Active respiratory infection requiring treatment with antibiotics within 4 weeks of the baseline visit (Visit 2). 12. Likely to be listed for transplant during trial participation.

Locations (7)

UCSF Parnassus

San Francisco, California, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

University of Michigan

Ann Arbor, Michigan, United States

Weill Cornell Medicine

New York, New York, United States

Outcomes

Primary Outcomes

Participants with treatment-emergent adverse event (TEAE)

The number of participants with at least 1 treatment-emergent adverse event

Time frame: Up to 12 weeks

The number of treatment-emergent adverse events (TEAE)

The number of treatment-emergent adverse events

Time frame: Up to 12 weeks

Participants with grade 3 or 4 treatment-emergent adverse events (TEAE)

The number of participants with at least 1 grade 3 or 4 treatment-emergent adverse events

Time frame: Up to 12 weeks

The number of grade 3 or 4 treatment-emergent adverse events (TEAE)

The number of grade 3 or 4 treatment-emergent adverse events

Time frame: Up to 12 weeks

Participants with serious adverse event (SAE)

The number of participants with at least 1 serious adverse event

Time frame: Up to 12 weeks

The number of serious adverse event (SAE)

The number of serious adverse events

Time frame: Up to 12 weeks

Participants with discontinued study treatment due to adverse events (AE)

The number of participants who discontinued study treatment due to adverse events

Time frame: Up to 12 weeks

Participants with discontinued study treatment due to serious adverse events (SAE)

The number of participants who discontinued study treatment due to serious adverse events

Time frame: Up to 12 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients

Overview

Conditions

Interventions

Eligibility

Locations (7)

Outcomes

Primary Outcomes

Secondary Outcomes